Carmell Therapeutics increased its IP portfolio with the issuance of Canada Patent No. 2,701,187, addressing Methods and Apparatus for Manufacturing Plasma Based Plastics.
The company is launching a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product/indication, designed to treat bone fractures while reducing complications, infections and duration of care. PBM uses pooled plasma to create products which accelerate the healing of bone and soft tissues.
Sources: Carmell Therapeutics Corp.; ORTHOWORLD Inc.
Carmell Therapeutics increased its IP portfolio with the issuance of Canada Patent No. 2,701,187, addressing Methods and Apparatus for Manufacturing Plasma Based Plastics.
The company is launching a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM)...
Carmell Therapeutics increased its IP portfolio with the issuance of Canada Patent No. 2,701,187, addressing Methods and Apparatus for Manufacturing Plasma Based Plastics.
The company is launching a Phase III clinical study for Bone Healing Accelerant, its first Plasma-based Bioactive Material (PBM) product/indication, designed to treat bone fractures while reducing complications, infections and duration of care. PBM uses pooled plasma to create products which accelerate the healing of bone and soft tissues.
Sources: Carmell Therapeutics Corp.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
